ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

ClinicalTrials.gov ID: NCT05552976

Public ClinicalTrials.gov record NCT05552976. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2

Study identification

NCT ID
NCT05552976
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
606 participants

Conditions and interventions

Interventions

  • Carfilzomib Drug
  • Dexamethasone Drug
  • Mezigdomide Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 9, 2023
Primary completion
Jul 17, 2026
Completion
Jul 24, 2029
Last update posted
Mar 31, 2026

2023 – 2029

United States locations

U.S. sites
34
U.S. states
20
U.S. cities
32
Facility City State ZIP Site status
Local Institution - 0046 Mobile Alabama 36604
Local Institution - 0005 Cerritos California 90703
Local Institution - 0190 Irvine California 92618
Local Institution - 0187 Los Angeles California 90017
Local Institution - 0344 Santa Rosa California 95403
Local Institution - 0339 Stockton California 95204
Local Institution - 0279 Newark Delaware 19713
Local Institution - 0341 Fort Myers Florida 33901
Local Institution - 0342 St. Petersburg Florida 33705
Local Institution - 0340 West Palm Beach Florida 33401
Local Institution - 0348 Atlanta Georgia 30303
Local Institution - 0291 Atlanta Georgia 30322
Saint Alphonsus Regional Medical Center Boise Idaho 83706
Local Institution - 0289 Annapolis Maryland 21401
Local Institution - 0204 Boston Massachusetts 02215
Local Institution - 0346 Minneapolis Minnesota 55404
Local Institution - 0222 Little Silver New Jersey 07739
Local Institution - 0199 The Bronx New York 10467
Local Institution - 0322 Cleveland Ohio 44106
Local Institution - 0172 Columbus Ohio 43214
Local Institution - 0321 Providence Rhode Island 02903
Local Institution - 0338 Greer South Carolina 29650
Local Institution - 0349 Chattanooga Tennessee 37404
Local Institution - 0323 Nashville Tennessee 37203
Local Institution - 0337 Fort Worth Texas 76104
Local Institution - 0328 Houston Texas 77025
Local Institution - 0044 Houston Texas 77030
Local Institution - 0195 Temple Texas 76508
Local Institution - 0345 Norfolk Virginia 23502
Local Institution - 0343 Roanoke Virginia 24014
Local Institution - 0006 Tacoma Washington 98405
Local Institution - 0347 Vancouver Washington 98684
Local Institution - 0243 Morgantown West Virginia 26506
Local Institution - 0336 Marshfield Wisconsin 54449

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 173 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05552976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 31, 2026 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05552976 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →